Cargando…
Discovering New Medicines Targeting Helicases: Challenges and Recent Progress
Helicases are ubiquitous motor proteins that separate and/or rearrange nucleic acid duplexes in reactions fueled by adenosine triphosphate (ATP) hydrolysis. Helicases encoded by bacteria, viruses, and human cells are widely studied targets for new antiviral, antibiotic, and anticancer drugs. This re...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society for Laboratory Automation and Screening. Published by Elsevier Inc.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427233/ https://www.ncbi.nlm.nih.gov/pubmed/23536547 http://dx.doi.org/10.1177/1087057113482586 |
_version_ | 1782370697566224384 |
---|---|
author | Shadrick, William R. Ndjomou, Jean Kolli, Rajesh Mukherjee, Sourav Hanson, Alicia M. Frick, David N. |
author_facet | Shadrick, William R. Ndjomou, Jean Kolli, Rajesh Mukherjee, Sourav Hanson, Alicia M. Frick, David N. |
author_sort | Shadrick, William R. |
collection | PubMed |
description | Helicases are ubiquitous motor proteins that separate and/or rearrange nucleic acid duplexes in reactions fueled by adenosine triphosphate (ATP) hydrolysis. Helicases encoded by bacteria, viruses, and human cells are widely studied targets for new antiviral, antibiotic, and anticancer drugs. This review summarizes the biochemistry of frequently targeted helicases. These proteins include viral enzymes from herpes simplex virus, papillomaviruses, polyomaviruses, coronaviruses, the hepatitis C virus, and various flaviviruses. Bacterial targets examined include DnaB-like and RecBCD-like helicases. The human DEAD-box protein DDX3 is the cellular antiviral target discussed, and cellular anticancer drug targets discussed are the human RecQ-like helicases and eIF4A. We also review assays used for helicase inhibitor discovery and the most promising and common helicase inhibitor chemotypes, such as nucleotide analogues, polyphenyls, metal ion chelators, flavones, polycyclic aromatic polymers, coumarins, and various DNA binding pharmacophores. Also discussed are common complications encountered while searching for potent helicase inhibitors and possible solutions for these problems. |
format | Online Article Text |
id | pubmed-4427233 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Society for Laboratory Automation and Screening. Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-44272332015-05-11 Discovering New Medicines Targeting Helicases: Challenges and Recent Progress Shadrick, William R. Ndjomou, Jean Kolli, Rajesh Mukherjee, Sourav Hanson, Alicia M. Frick, David N. SLAS Discov Review Article Helicases are ubiquitous motor proteins that separate and/or rearrange nucleic acid duplexes in reactions fueled by adenosine triphosphate (ATP) hydrolysis. Helicases encoded by bacteria, viruses, and human cells are widely studied targets for new antiviral, antibiotic, and anticancer drugs. This review summarizes the biochemistry of frequently targeted helicases. These proteins include viral enzymes from herpes simplex virus, papillomaviruses, polyomaviruses, coronaviruses, the hepatitis C virus, and various flaviviruses. Bacterial targets examined include DnaB-like and RecBCD-like helicases. The human DEAD-box protein DDX3 is the cellular antiviral target discussed, and cellular anticancer drug targets discussed are the human RecQ-like helicases and eIF4A. We also review assays used for helicase inhibitor discovery and the most promising and common helicase inhibitor chemotypes, such as nucleotide analogues, polyphenyls, metal ion chelators, flavones, polycyclic aromatic polymers, coumarins, and various DNA binding pharmacophores. Also discussed are common complications encountered while searching for potent helicase inhibitors and possible solutions for these problems. Society for Laboratory Automation and Screening. Published by Elsevier Inc. 2013-08 2022-04-25 /pmc/articles/PMC4427233/ /pubmed/23536547 http://dx.doi.org/10.1177/1087057113482586 Text en Copyright © 2013 Society for Laboratory Automation and Screening. Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Article Shadrick, William R. Ndjomou, Jean Kolli, Rajesh Mukherjee, Sourav Hanson, Alicia M. Frick, David N. Discovering New Medicines Targeting Helicases: Challenges and Recent Progress |
title | Discovering New Medicines Targeting Helicases: Challenges and Recent Progress |
title_full | Discovering New Medicines Targeting Helicases: Challenges and Recent Progress |
title_fullStr | Discovering New Medicines Targeting Helicases: Challenges and Recent Progress |
title_full_unstemmed | Discovering New Medicines Targeting Helicases: Challenges and Recent Progress |
title_short | Discovering New Medicines Targeting Helicases: Challenges and Recent Progress |
title_sort | discovering new medicines targeting helicases: challenges and recent progress |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427233/ https://www.ncbi.nlm.nih.gov/pubmed/23536547 http://dx.doi.org/10.1177/1087057113482586 |
work_keys_str_mv | AT shadrickwilliamr discoveringnewmedicinestargetinghelicaseschallengesandrecentprogress AT ndjomoujean discoveringnewmedicinestargetinghelicaseschallengesandrecentprogress AT kollirajesh discoveringnewmedicinestargetinghelicaseschallengesandrecentprogress AT mukherjeesourav discoveringnewmedicinestargetinghelicaseschallengesandrecentprogress AT hansonaliciam discoveringnewmedicinestargetinghelicaseschallengesandrecentprogress AT frickdavidn discoveringnewmedicinestargetinghelicaseschallengesandrecentprogress |